These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17293189)

  • 1. Effectiveness of glycoprotein IIb/IIIa inhibitor use during primary coronary angioplasty: results of propensity analysis using the New York State Percutaneous Coronary Intervention Reporting System.
    Srinivas VS; Skeif B; Negassa A; Bang JY; Shaqra H; Monrad ES
    Am J Cardiol; 2007 Feb; 99(4):482-5. PubMed ID: 17293189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
    Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mayo Clinic Risk Score predicts in-hospital mortality following primary angioplasty.
    Kumar SS; Negassa A; Monrad ES; Srinivas VS
    J Invasive Cardiol; 2005 Oct; 17(10):522-6. PubMed ID: 16204745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
    Montalescot G; Van de Werf F; Gulba DC; Avezum A; Brieger D; Kennelly BM; Mazurek T; Spencer F; White K; Gore JM;
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):360-7. PubMed ID: 14571488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
    Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
    Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G; Marino P
    Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.
    Gumina RJ; Yang EH; Sandhu GS; Prasad A; Bresnahan JF; Lennon RJ; Rihal CS; Holmes DR; Singh M
    Mayo Clin Proc; 2008 Sep; 83(9):995-1001. PubMed ID: 18775199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kozieradzka A; Kamiński KA; Pepiński W; Janica J; Korecki J; Skolimowski K; Frankowska E; Kralisz P; Bonda TA; Dobrzycki S; Musiał WJ
    Kardiol Pol; 2006 Dec; 64(12):1350-5; discussion 1356. PubMed ID: 17206538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.
    De Luca G; Gibson M; Cutlip D; Huber K; Dudek D; Bellandi F; Noc M; Maioli M; Zorman S; Zeymer U; Secco GG; Mesquita Gabriel H; Emre A; Arntz HR; Rakowski T; Gyongyosi M; Hof AW;
    Arch Cardiovasc Dis; 2013 Mar; 106(3):155-61. PubMed ID: 23582677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes.
    De Carlo M; Borelli G; Gistri R; Ciabatti N; Mazzoni A; Arena M; Petronio AS
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):408-15. PubMed ID: 19360863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experience.
    Eichhöfer J; Horlick E; Ivanov J; Seidelin PH; Ross JR; Ing D; Daly P; Mackie K; Ridley B; Schwartz L; Barolet A; Dzavík V
    Am Heart J; 2008 Nov; 156(5):864-70. PubMed ID: 19061699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of outcomes and safety of "facilitated" versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    McKay RG; Dada MR; Mather JF; Mennet RR; Murphy DJ; Maloney KW; Hirst JA; Kiernan FJ
    Am J Cardiol; 2009 Feb; 103(3):316-21. PubMed ID: 19166682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Percutaneous coronary interventions in elderly patients: clinical indications and adjunctive medical treatment. The Italian Drug Evaluation in Angioplasty (IDEA) study].
    Bossi I; Piccaluga E; Scatturin M; Corvaja N; Pasquetto G; Steffanon L; Oberhollenzer R; Colombo P; Bolognese L; Savonitto S
    G Ital Cardiol (Rome); 2006 Feb; 7(2):136-44. PubMed ID: 16532725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.
    Hoekstra JW; Roe MT; Peterson ED; Menon V; Mulgund J; Pollack CV; Miller C; Palabrica T; Harrington RA; Ohman EM; Gibler WB
    Acad Emerg Med; 2005 May; 12(5):431-8. PubMed ID: 15863399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.